Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Dextromethorphan is an antitussive with a high margin of safety that has been hypothesized to display rapid-acting antidepressant activity based on pharmacodynamic similarities to the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine. In addition to binding to NMDA receptors, dextromethorphan binds to sigma-1 (σ1) receptors, which are believed to be protein targets for a potential new class of antidepressant medications. The purpose of this study was to determine whether dextromethorphan elicits antidepressant-like effects and the involvement of σ1 receptors in mediating its antidepressant-like actions. The antidepressant-like effects of dextromethorphan were assessed in male, Swiss Webster mice using the forced swim test. Next, σ1 receptor antagonists (BD1063 and BD1047) were evaluated in conjunction with dextromethorphan to determine the involvement of σ receptors in its antidepressant-like effects. Quinidine, a cytochrome P450 (CYP) 2D6 inhibitor, was also evaluated in conjunction with dextromethorphan to increase the bioavailability of dextromethorphan and reduce exposure to additional metabolites. Finally, saturation binding assays were performed to assess the manner in which dextromethorphan interacts at the σ1 receptor. Our results revealed dextromethorphan displays antidepressant-like effects in the forced swim test that can be attenuated by pretreatment with σ1 receptor antagonists, with BD1063 causing a shift to the right in the dextromethorphan dose response curve. Concomitant administration of quinidine potentiated the antidepressant-like effects of dextromethorphan. Saturation binding assays revealed that a Ki concentration of dextromethorphan reduces both the Kd and the Bmax of [(3)H](+)-pentazocine binding to σ1 receptors. Taken together, these data suggest that dextromethorphan exerts some of its antidepressant actions through σ1 receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Due to its short half-life, DM lacks AD efficacy as a monotherapy, but in conjunction with quinidine, a CYP2D6 enzyme inhibitor that limits DM metabolism, it produces more lasting AD effects [148,149].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [148]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Due to its short half-life, DM lacks AD efficacy as a monotherapy, but in conjunction with quinidine, a CYP2D6 enzyme inhibitor that limits DM metabolism, it produces more lasting AD effects [148,149].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 5×
“Imipramine did not alter locomotor activity, even at doses that produced antidepressant-like effects (Figure 1B; F[2,30] = 0.”
BackgroundResultInfluentialControl of inositol 1,4,5-trisphosphate-induced Ca2+ release by cytosolic Ca2+
Bootman, M. D., Missiaen, L., Parys, J. B., De Smedt, H., & Casteels, R. (1995) · Biochemical Journal · doi:10.1042/bj3060445 · Cited by 5,120
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 3×
“ANOVA confirmed a significant difference between the various treatment groups (F[7,77] = 8.”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 1×
“, hallucinations and dissociations) [6,7,8].”
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“Depression affects up to one fifth of the world population, stands as the second leading cause of disability worldwide, and imposes a substantial economic burden [1,2].”
BackgroundAssessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 5×
“Consistent with earlier reports that the forced swim test does not reliably detect the effects of SSRIs [37], the SSRI fluoxetine did not significantly reduce immobility time in the forced swim test under the conditions used by our laboratory (F[2,32] = 1.97, n.s.).”
BackgroundResultInfluentialThe ascent of mouse: advances in modelling human depression and anxiety
Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198 · cited 2×
“, sucrose preference test, novelty suppression) [3,29,30] will be needed in the future to further evaluate the antidepressant potential of dextromethorphan and the involvement of s1 receptors.”
BackgroundBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · cited 2×
“ANOVA confirmed a significant difference between the various treatment groups in the antagonism study for dextromethorphan in the forced swim test (F[3,41] = 5.”
ResultPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“3–20 nM) [40,41,42,43], and s1 receptors (343 nM) [44].”
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Cummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use
Taylor, C. P., Traynelis, S. F., Siffert, J., Pope, L. E., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.010 · Cited by 186
“In the presence of 400 nM DM, radioligand binding of the high-affinity Sig1-R agonist [(3)H](+)pentazocine occurred with reductions in both Kd and Bmax, suggesting complex interactions with Sig1-Rs which may involve competitive as well as non-competitive binding (Nguyen et al., 2014).”
BackgroundMethodInfluentialSelf-citationGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
“At the same timepoint, the mice showed behavioral improvement in the FST.”
BackgroundInfluentialCutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 194
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
“In preclinical studies, we have found that DM exerts antidepressant-like effects in mice using the forced swim test (FST) and tail suspension test, two of the most validated and widely used animal models for predicting antidepressant efficacy (Nguyen et al., 2014; Nguyen & Matsumoto, 2015).”
BackgroundInfluentialSelf-citationTabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140
The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Penke, B., Fulop, L., Szucs, M., & Frecska, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170529104323 · Cited by 129
Molecular aspects of depression: A review from neurobiology to treatment
Villas Boas, G. R., Boerngen de Lacerda, R., Paes, M. M., Gubert, P., Almeida, W. L. D. C., Rescia, V. C., de Carvalho, P. M. G., de Carvalho, A. A. V., & Oesterreich, S. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.024 · Cited by 128
Exciting Times for Pancreatic Islets: Glutamate Signaling in Endocrine Cells
Otter, S., & Lammert, E. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.12.004 · Cited by 113
“In the liver, DXM is metabolized to DXO by cytochrome P450 [89], and DXO exhibits a stronger antagonizing effect on NMDARs than DXM (DXO: IC50 = 0.”
BackgroundStrasburger, S. E., Bhimani, P. M., Kaabe, J. H., Krysiak, J. T., Nanchanatt, D. L., Nguyen, T. N., Pough, K. A., Prince, T. A., Ramsey, N. S., Savsani, K. H., et al. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12497 · Cited by 84
“Themice were tested using forced-swim tests and locomotor-activity tests before and after injections of the drugs.(23) Both imipramine and dextromethorphan had an effect on mouse behaviour, whereas normal saline and the sigma1 antagonists did not.”
MethodResultInfluentialInvestigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P.-M. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 74
“Dextromethorphan is a noncompetitive NMDA receptor antagonist and σ1-receptor agonist, commonly used antitussive compound [113,114] (for σ1-receptors in depression, see references [115,116]).”
BackgroundMaurice, T. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1838483 · Cited by 72
“sion [155–157]; dextromethorphan-quinidine (Nuedexta®) in pseudo-bulbar affect [158,159]; or donepezil (Aricept®) in AD”
BackgroundMurrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62
“More recently, pretreatment with the σ1 receptor antagonist BD1063 was shown to attenuate the antidepressant behavioral effects of DM in the forced swim test (FST) (Nguyen et al., 2014).”
BackgroundMarcinkowska, M., Śniecikowska, J., Fajkis-Zajączkowska, N., Paśko, P., Franczyk, W., & Kołaczkowski, M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00707-7 · Cited by 73
“Further studies in rodents revealed that dextromethorphan displayed anti-depressive-like activity and exerted neuroprotective and antioxidant effects [122, 123].”
BackgroundSigma-1 receptor: A potential target for the development of antidepressants
Wang, Y., Xia, C., Jia, H., He, J., Lian, W., Yan, Y., Wang, W., Zhang, W., & Xu, J. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105390 · Cited by 58
AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type
Garay, R. P., & Grossberg, G. T. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1267726 · Cited by 58
Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects
Silva, A. R., & Dinis‐Oliveira, R. J. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1758712 · Cited by 61
“Moreover, it was shown that DXM itself would sufficiently produce this antidepressant-like effect, not requiring conversion to the metabolite DXO (Nguyen et al. 2014).”
BackgroundInfluentialPandey, P., Prasad, K., Prakash, A., & Kumar, V. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01980-1 · Cited by 59
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice
Nguyen, L., & Matsumoto, R. R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.024 · Cited by 51
Self-citationPharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Due to its short half-life, DM lacks AD efficacy as a monotherapy, but in conjunction with quinidine, a CYP2D6 enzyme inhibitor that limits DM metabolism, it produces more lasting AD effects [148,149].”
BackgroundMajeed, A., Xiong, J., Teopiz, K. M., Ng, J., Ho, R., Rosenblat, J. D., Phan, L., Cao, B., & McIntyre, R. S. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1898588 · Cited by 48
“(2014, 2015, 2016, 2017) – and funded by Avanir Pharmaceuticals Inc [27,28,30,31].”
BackgroundInfluentialDextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect
Yang, L. P. H., & Deeks, E. D. (2014) · Drugs · doi:10.1007/s40265-014-0328-z · Cited by 46
“Indeed, a recent animal study showed that dextromethorphan conferred antidepressantlike effects that were mediated, at least partly, through the r-1 receptor [12].”
BackgroundRecreational use of dextromethorphan, “Robotripping”-A brief review
Stanciu, C. N., Penders, T. M., & Rouse, E. M. (2016) · American Journal on Addictions · doi:10.1111/ajad.12389 · Cited by 42
Chaperone Sigma1R and Antidepressant Effect
Воронин, М. В., Vakhitova, Y. V., & Середенин, С. Б. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197088 · Cited by 44
Prasanth, M. I., Malar, D. S., Tencomnao, T., & Brimson, J. M. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1939681 · Cited by 43
“of 205 μM [169] and has been shown to have antidepressant properties related to σ-1 R agonism [170] and induce autop-”
BackgroundAkbar, D., Rhee, T. G., Ceban, F., Ho, R., Teopiz, K. M., Cao, B., Subramaniapillai, M., Kwan, A. T. H., Rosenblat, J. D., & McIntyre, R. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01032-5 · Cited by 38
“Preclinical studies have reported diminishing antidepressant effects of DXM when pretreated with a sigma-1 receptor antagonist [58].”
BackgroundNguyen, L., Lucke-Wold, B. P., Logsdon, A. F., Scandinaro, A. L., Huber, J. D., & Matsumoto, R. R. (2016) · Neuroreport · doi:10.1097/wnr.0000000000000646 · Cited by 31
Self-citationAVP-786 as a promising treatment option for Alzheimer’s Disease including agitation
Khoury, R., Marx, C., Mirgati, S., Velury, D., Chakkamparambil, B., & Grossberg, G. T. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1882995 · Cited by 31
“It is also believed that DM’s antidepressant activity may be partly mediated by Sig-1R: studies in mice using the forced swim test showed that the antidepressant-like effects caused by DM were attenuated by pretreatment with Sig-1R antagonist BD1063 [46].”
BackgroundZhu, S., Wang, C., Han, Y., Song, C., Hu, X., & Liu, Y. (2015) · Mediators of Inflammation · doi:10.1155/2015/265056 · Cited by 31
Investigational drugs for treating major depressive disorder
Dhir, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1267727 · Cited by 32
“contrast, imipramine at a lower dose of 20 mg/kg reduced the immobility period and the effect was independent of alteration in the locomotor activity in these mice [75].”
BackgroundInfluentialNMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Welters, A., Kluppel, C. A., Mrugala, J., Wörmeyer, L., Meißner, T., Mayatepek, E., Heiß, C., Eberhard, D., & Lammert, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13017 · Cited by 37
“from the gut, it undergoes rapid and extensive first-pass metabolism in the liver (by cytochrome P450 2D6 isoenzyme) to its major active metabolite dextrorphan (DXO).(34) It is a morphinan, but has little affinity to opioid receptors and instead blocks NMDARs.”
BackgroundClassics in Chemical Neuroscience: Dextromethorphan (DXM)
McClure, E. W., & Daniels, R. N. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00088 · Cited by 32
Deuterated (d6)-dextromethorphan elicits antidepressant-like effects in mice
Nguyen, L., Scandinaro, A. L., & Matsumoto, R. R. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.09.005 · Cited by 25
Self-citationEnkirch, T., Sauber, S., Anderson, D. E., Gan, E. S., Kenanov, D., Maurer‐Stroh, S., & von Messling, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01097 · Cited by 27
Cardiac Sigma Receptors – An Update
Stračina, T., & Nováková, M. (2018) · Physiological Research · doi:10.33549/physiolres.934052 · Cited by 23
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Pridopidine in Amyotrophic Lateral Sclerosis
Hayden, D., Lai, P.-Y., Donahue, R. A., Chen, H.-W., Wang, J., Mathai, N. M., Lopes, G., McCaffrey, A., Scalia, J., Luppino, S. D., et al. (2025) · JAMA · doi:10.1001/jama.2024.26429 · Cited by 29
Fluyau, D., Revadigar, N., & Pierre, C. G. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107845 · Cited by 23
An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer
Robinson, T. S., & Osman, M. A. (2023) · Cancers · doi:10.3390/cancers15133464 · Cited by 18
Dextromethorphan and memantine after ketamine analgesia: a randomized control trial
Martin, E., Sorel, M., Morel, V., Marcaillou, F., Picard, P., Delage, N., Tiberghien-Chatelain, F., Crosmary, M.-C., Najjar, M., Colamarino, R., et al. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s207350 · Cited by 19
Mania After Misuse of Dextromethorphan
Stanciu, C. N., & Penders, T. M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000104 · Cited by 16
“These mechanisms have made DXM the subject of study as a potentially rapidly acting antidepressant drug (Nguyen et al., 2014).”
BackgroundQuadir, S. G., Tanino, S. M., Sami, Y. N., Minnig, M. A., Iyer, M. R., Rice, K. C., Cottone, P., & Sabino, V. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14635 · Cited by 16
A behavioral and pharmacological characterization of palatable diet alternation in mice
Moore, C. F., Schlain, G. S., Mancino, S., Sabino, V., & Cottone, P. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.10.013 · Cited by 16
“Chosen doses and pretreatment time were based on previous literature (Brammer et al., 2006; Liu et al., 2005; Liu and Matsumoto, 2008; Nguyen et al., 2014).”
MethodNew Medications for Neuropsychiatric Disorders
Reddy, H. M., Poole, J. S., Maguire, G. A., & Stahl, S. M. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.008 · Cited by 17
Sigma non-opioid receptor 1 is a potential therapeutic target for long QT syndrome
Song, L., Bekdash, R., Morikawa, K., Quejada, J. R., Klein, A. D., Aina-Badejo, D., Yoshida, K., Yamamoto, H. E., Chalan, A., Yang, R., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00016-2 · Cited by 16
Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice
Saavedra, J. S., Garrett, P. I., Honeycutt, S. C., Peterson, A. M., White, J., & Hillhouse, T. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173003 · Cited by 15
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 16
“…[13], CP-101,606 [73] and ifenprodil [74]; as well as open-channel blockers at NMDAR PCP/Mg 2+ site, including ketamine [13,15,17,48], methoxetamine (MXE) and its analogues [49,50], MK-801 [15,51,52,61], lanicemine (AZD6765) [53], dextromethorphan (DM) [54,69–71] and memantine [64– 66 , 68].”
BackgroundTran, H., Chung, Y. H., Shin, E., Tran, T.-V., Jeong, J. H., Jang, C., Nah, S.-Y., Yamada, K., Nabeshima, T., & Kim, H. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.010 · Cited by 11
NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review
Delfino, R. S., Surjan, J. C., Bandeira, I. D., Braziliano, L., Correia‐Melo, F. S., Del-Porto, J. A., Quarantini, L. C., & Lacerda, A. L. T. (2020) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-020-00201-w · Cited by 11
Yang, Y., Yang, Y.-C. S. H., Wu, P.-L., Yang, C.-H., Kuo, K.-C., & Yang, S. (2020) · Mediators of Inflammation · doi:10.1155/2020/9694012 · Cited by 9
“DM acts as a low-affinity noncompetitiveN-methyl-D-aspartate (NMDA) receptor antagonist [13, 14], sigma-1 receptor agonist [15], and α3β4-nicotinic receptor antagonist [14].”
BackgroundOlives, T. D., Boley, S. P., LeRoy, J. M., & Stellpflug, S. J. (2019) · Journal of Medical Toxicology · doi:10.1007/s13181-019-00706-1 · Cited by 8
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 14
“However, beyond NMDAR antagonism, the antidepressant ef fi cacy of this combination may also involve sigma-1 receptor agonism and monoamine reuptake inhibition [87 – 90].”
New advances in small molecule drugs targeting NMDA receptors
Zeng, Y., Qu, Z.-Y., Zhu, Q., Wang, H., Zhou, Y., & Gao, Z.-B. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01675-8 · Cited by 9
“Additionally, it acts as a sigma-1 receptor agonist and inhibits serotonin and norepinephrine reuptake [130].”
DEXTROMETHORPHAN- AN EMERGING DRUG OF ABUSE
Raiborde, M. D., Kumar, G., Singh, P., & Sharma, S. (2022) · Journal of Pharmaceutical Negative Results · doi:10.47750/pnr.2022.13.s06.087 · Cited by 7
Role of NMDA Receptors in Pancreatic Islets
Scholz, O., Welters, A., & Lammert, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_7 · Cited by 10
Chuang, W.-C., Yeh, C., Wang, S.-C., Pan, P., Shyu, J., Liu, Y., Gau, S. S., & Lu, R. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00437 · Cited by 9
“DM is an uncompetitive, low-affinity NMDA receptor antagonist and coupled with the high-affinity agonist activity at sigma-1 receptors, clinical improvements in neurobehavioral disorders might be attributed to neuroprotection against glutamate excitotoxity (68) and the immunomodulatory effects on the inhibition of ser…”
BackgroundTapia, M. A., Lever, J. R., Lever, S. Z., Will, M. J., Park, E. S., & Miller, D. K. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05268-2 · Cited by 7
The sigma–1 receptor: a mechanistically–informed therapeutic target for antidepressants
Xiao, N., Yin, L., Teopiz, K. M., Kwan, A. T. H., Le, G. H., Wong, S., Valentino, K., Choi, H., Rosenblat, J. D., Ho, R., et al. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2500424 · Cited by 6
“A post hoc Tukey’s test confirmed that BD1063 treatment blocked the ability of dextromethorphan to increase locomotor activity [25].”
Singh, M. A., & Johnson, D. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23cr15139 · Cited by 6
Shakiba, S., Fakhraei, N., Khan, M. I., Rastmanesh, F., Mohammadi, F. S., Khalilzadeh, M., Afshari, K., Haddadi, N., Haj‐Mirzaian, A., Ünal, U. K., et al. (2021) · Learning and Motivation · doi:10.1016/j.lmot.2021.101722 · Cited by 5
Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.
Siegel, J. S., Pearson, C. S., & Lenze, E. J. (2023) · PubMed Central · Cited by 7
Dextromethorphan/bupropion in major depressive disorder: a profile of its use
Blair, H. A. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01009-w · Cited by 5
“However, preclinical evidence does suggest the glutamatergic pathway is involved in the antidepressant effects of dextromethorphan [14, 15].”
BackgroundGupta, L., Tomar, N., & Sarin, R. K. (2024) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2024.100161 · Cited by 9
Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study
Berkovich, R., Sokolov, A. Y., Togasaki, D. M., Альбертовна, Я. А., Cesar, P.-H., & Sahai‐Srivastava, S. (2018) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000272 · Cited by 5
Witkin, J. M., Cerne, R., Newman, A. H., Izenwasser, S., Smith, J. L., & Tortella, F. C. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173154 · Cited by 5
Lai, Y., Yao, Z., Chang, T., Feng, C., Kuo, T., Luo, Y., Jean, Y., Lin, H. Y., & Wen, Z. (2024) · Environmental Toxicology · doi:10.1002/tox.24447 · Cited by 4
“Similar to NMDA receptors, osteoblasts and osteoclasts also contain serotonin and sigma-1 receptors, which participate in bone homeostasis [36].”
Pharmacological characterizations of the 'legal high' fluorolintane and isomers
Wallach, J. V., Colestock, T., Agramunt, J., Claydon, M. D. B., Dybek, M. B., Filemban, N., Chatha, M., Halberstadt, A. L., Brandt, S. D., Lodge, D., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172427 · Cited by 4
“The relevance of this remains unclear, but sigma-1 has been hypothesized as important in the actions of the NMDA receptor antagonist dextromethorphan (DXM) (Su et al. 2010, Nguyen et al. 2014).”
BackgroundMesripour, A., Hajhashemi, V., & Rezaie, S. (2018) · The Thai Journal of Pharmaceutical Sciences · doi:10.56808/3027-7922.2390 · Cited by 4
“[31,32] Distinct chemically, sigma-1 receptor agonists such as (+)-pentazocine, 1,3-di-otolyguanidine, SA-4503, dextromethorphan igmesine, and many others, dose-dependently reduce immobility in animal models of depression, including FST; their antidepressant action was reversed by the selective sigma-1 receptor antago…”
BackgroundNovel Pharmacologic Strategies for Treating Behavioral Disturbances in Alzheimer’s Disease
Thiyagarajah, M. T., Herrmann, N., Ruthirakuhan, M. T., Li, A., & Lanctôt, K. L. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00181-6 · Cited by 4
Lynch, C. J., & Prus, A. J. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000649 · Cited by 5
“Preclinically, 30 mg/kg of dextromethorphan alone (or 10 and 30 mg/kg dextromethorphan in combination with 30 mg/kg quinidine) increases immobility in a forced swim test in mice, although only the dextromethorphan 10 mg/ kg dose in combination with quinidine showed this effect in the absence of increased open-field ac…”
BackgroundMethodHegde, N. C., Mishra, B. R., Mohapatra, D., Srinivasan, A., & Maiti, R. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.104919 · Cited by 4
Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
Yates, C. G., Kruse, J. L., Price, J. B., Robertson, A. A. B., & Tye, S. J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00249-9 · Cited by 4
Kwan, A. T. H., & McIntyre, R. S. (2024) · CNS Spectrums · doi:10.1017/s1092852924000415 · Cited by 4
Wu, J., Tsai, W.-Y., Chen, J.-H., & Wong, C. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.01.011 · Cited by 3
Teopiz, K. M., Le, G. H., Wong, S., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120836 · Cited by 2
Algieri, C., Cugliari, A., Granata, S., Glogowski, P. A., Trombetti, F., Fabbri, M., Scainelli, L., & Nesci, S. (2026) · BioFactors · doi:10.1002/biof.70076 · Cited by 3
“…σ 1 receptors, which are membrane proteins that act as a molecular chaperone and modulator of various neuronal and cellular signaling systems [9], inhibits the serotonin transporter [10], thus impairing reuptake into nerve cells, and interacts with voltage-gated calcium channels [11, 12],…”
Piechal, A., Jakimiuk, A. A., & Pyrzanowska, J. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00852-8 · Cited by 2
“Similarly, Nguyen et al. [23 ] demon - strated that dextromethorphan, a compound with affinity for both NMDA and S1Rs, exerted antidepressant-like effects in the FST.”
de Miranda, A. S., Toscano, E. C. D. B., Venna, V. R., Graeff, F. G., & Teixeira, A. L. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2460674 · Cited by 4
“Preclinical evidence has also demonstrated that dextro-methorphan acts in the opioid system, stimulating sigma-1 receptors, which, in turn, modulate glutamatergic pathways [112].”
Dextromethorphan as an Opioid-Sparing Analgesic in Postoperative Pain
Rajput, R., Harakeh, K. A., Figueras, G., Mahi, A., Minhas, M., Sobolevskaia, D., Prasad, S. B., & Rajput, A. (2025) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000638 · Cited by 3
Advancing depression treatment: the role of sigma receptor ligands
Zhang, P., Ning, Z., Chen, H., Chen, J., Lu, Z., & Xu, F. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1691987 · Cited by 1
“Dextromethorphan, a component of AXS-05, exhibits rapid antidepressant effects via sigma receptors in animal models (Nguyen et al., 2014).”
Novel and Investigational Drugs in Depression
Shapiro, D. N., & Stahl, S. M. (2014) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2014/11590 · Cited by 1
“There is animal evidence indicating that at least some of dextromethorphan’s antidepressant actions involve sigma-1 receptors [57].”
BackgroundDextromethorphan for chronic neuropathic pain in palliative care
Antoniu, S. A., Apostu, M., Alexinschi, O., & Mosoiu, D. V. (2016) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2017.1264259 · Cited by 1
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00601-6 · Cited by 1
Chen, M., & Tsai, S. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111242 · Cited by 2
Xiao, Y., Hu, X., Xing, W., Yan, J., Wang, R., Li, X., Li, J., Zhang, Z., Sun, J., & Wu, J. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1464564 · Cited by 1
“Dextromethorphan (DM) is an over-the-counter antitussive drug, with a mechanism of action similar to that of esketamine, both of which block NMDA receptors (Nguyen et al., 2014; Nguyen et al., 2017).”
BackgroundDextromethorphan Alters Depressive and Cognitive Associated Behaviours; A Sexually Dimorphic Study
Ijomone, O. M., & Biose, I. J. (2018) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.9.10.275 · Cited by 3
Neogi, R. (2020) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2020.363
Evaluation of the antidepressant potential of dextromethorphan
Nguyen, L. (2015) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6309
Self-citationMesripour, A., & Ahmadi, T. (2022) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.301249 · Cited by 1
Hu, X., Xing, W., Wang, R., Li, X., Li, J., Yan, J., Wu, J., & Xiao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4119597/v1
Drug Repurposing for Long QT Syndrome Using Patient-Specific iPSCs Technology
Morikawa, K. (2025) · Japanese Journal of Electrocardiology · doi:10.5105/jse.45.5
Lipman, J. J. (2026) · Wiley eBooks · doi:10.1002/9781118832202.ch29
Martin, E. (2017) · theses.fr (ABES) · doi:10.70675/3f77e643zf119z465fzbc28z20877ecebf8e
Otarigho, B., Lalsiamthara, J., & Aballay, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.29.728750
“Although DXM is widely used as an NMDA receptor antagonist, it is not fully selective and may exhibit off-target effects 33, 34 .”
Dextromethorphan Beyond the Cough: Exploring Its Psychedelic Potential: A Systematic Review
Hackett, E. P., -, A. C., Hasman, L., Thakur, R., Scott, M. J., & Dworkin, R. H. (2026) · CNS Drugs · doi:10.1007/s40263-026-01305-9
Clayton, A. H., Alva, G., Bowman, P., Crown, E., Das, B., Doghramji, P. P., Kempf, B., Muzyk, A. J., Schreiber, J., & Miller, J. J. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2700073
“This is an important pharmacological target given the role of sigma-1 in facilitating neurotransmission and mitigating neuroinflammation; a growing body of evidence suggests that the sigma-1 receptor is a target for rapid-onset antidepressant drugs 23–28 .”
Kavuran, İ. B., Önalan, E., Turk, Z. I., & Eröksüz, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1910199
“Dextromethorphan has been shown to reduce immobility time in the FST, and this antidepressant-like effect can be attenuated Frontiers in Pharmacology frontiersin.org 11 Buran Kavuran et al. 10.3389/fphar.2026.1910199 by sigma-1 receptor antagonism (Nguyen, 2014).”
Influential
Metadata
- Authors
- Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R.
- Affiliations
- West Virginia University (US)
- Corresponding author
- Matsumoto, Rae R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-28
- Volume
- 9
- Issue
- 2
- Pages
- e89985
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3938562
- OpenAlex
- W2122215517
- Cited by
- 99
- References
- 50
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 4 · 2021: 8 · 2020: 12 · 2019: 8 · 2018: 5 · 2017: 11 · 2016: 8 · 2015: 7 · 2014: 2
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Research Repository @ WVU (West Virginia University) (submittedVersion, cc-by)
- Touro Scholar (Touro College) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- West Virginia University
- Avanir Pharmaceuticals
- National Institutes of Health
- National Institute on Drug Abuse (DA013978, R01DA013583, DA013583, R01DA013978)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- dextromethorphan, sigma-1 receptor, antidepressant-like effects, rapid-acting antidepressants, sigma-1 receptor antagonists, BD1047, quinidine, CYP2D6 inhibition, forced swim test, NMDA receptor, ketamine
- MeSH terms
- Sigma-1 Receptor, Adrenergic alpha-Antagonists, Animals, Antidepressive Agents, Behavior, Animal, Cytochrome P-450 Enzyme System, Dextromethorphan, Dose-Response Relationship, Drug, Ethylenediamines, Ketamine, Kinetics, Male, Piperazines, Protein Binding, Quinidine, Swimming, Receptors, N-Methyl-D-Aspartate, Receptors, sigma, Excitatory Amino Acid Antagonists, Mice, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.